No heterogeneity was observed by type of control intervention (SGLT2 inhibitor vs GLP-1 RA), baseline history of CVD, CKD or heart failure, or baseline HbA1c (>64 mmol/mol vs ≤64 mmol/mol) (Fig. 4 and ESM Figs 4, 5). The gene discussed is SLC5A2; the disease is chronic kidney disease.